AbCellera Biologics Inc. ABCL Federal
Federal at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredFederalIncomeTaxExpenseBenefit.
The official record: AbCellera Biologics Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s federal.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s federal?
- AbCellera Biologics Inc. (ABCL) reported federal of $0 in Q4 2025.
- How has AbCellera Biologics Inc.'s federal changed year-over-year?
- AbCellera Biologics Inc.'s federal decreased by 100.0% year-over-year, from $187.25K to $0.
- What is the long-term trend for AbCellera Biologics Inc.'s federal?
- Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s federal has grown at a -100.0% compound annual growth rate (CAGR), from $4.53M to $0.
- What does federal mean?
- Represents the portion of federal income tax expense or benefit that is deferred to future periods due to temporary differences between the carrying amounts of assets and liabilities for financial reporting and tax purposes. This metric helps investors understand the impact of timing differences on the company's federal tax obligations.